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ABSTRACT Neuronal expression of cytokines is an area
of active investigation in the contexts of development, disease,
and normal neural function. Although cultured rat sympa-
thetic neurons respond very weakly to exogenous interleukin
6 (IL-6), we find that addition of soluble IL-6 receptor
(sIL-6R) and IL-6 enhances neuronal survival in the absence
of nerve growth factor. Neutralizing monoclonal antibodies
against IL-6 block these effects. Addition of IL-6 and sIL-6R
also induces a subset of neuropeptide and transmitter syn-
thetic enzyme mRNAs identical to that demonstrated for
leukemia inhibitory factor, ciliary neurotrophic factor, and
oncostatin M. Both of these effects are duplicated by addition
of a highly active fusion protein of sIL-6R and IL-6, covalently
linked by a flexible peptide chain, which is designated H-IL-6.
In addition, we show that sympathetic neurons produce IL-6.
In situ hybridization indicates a neuronal localization of IL-6
mRNA in superior cervical ganglia, and bioactive IL-6 protein
is detected in ganglion culture supernatants. Interestingly, the
IL-6 produced by sympathetic neurons does not lead to
survival of these cells in culture unless sIL-6R is added. Thus,
sympathetic neurons can produce IL-6 and may respond to it
in an autocrineyparacrine manner if sIL-6R is present. More-
over, the prior findings of sIL-6R in serum and inflammatory
f luids now have added interest in the context of neuro–
immune interactions.
Interleukin 6 (IL-6) is a multifunctional cytokine that plays a
central role in inflammatory responses and in the regulation of
cells of the hematopoietic system (1). A number of studies have
also provided evidence for the expression and action of IL-6 in
the nervous system. IL-6 and IL-6 receptor (IL-6R) mRNAs
are detected in discrete regions of the rat central nervous
system (CNS), where both genes are developmentally regu-
lated and localized in specific neuronal subpopulations (2–4).
IL-6 has also been implicated in the regulation of neuronal
survival (5–7) and in response of the CNS to trauma, inflam-
mation, and degenerative disease (8–11).
IL-6 belongs to the neuropoietic cytokine family, which also
includes ciliary neurotrophic factor (CNTF), leukemia inhib-
itory factor (LIF), oncostatin M (OSM), interleukin 11 (IL-
11), and cardiotrophin 1 (CT-1) (12–14). Overlapping biolog-
ical activities and a similar secondary structure have been
reported for these cytokines (12, 15–18). Moreover, these
proteins utilize the same signal-transducing receptor subunit
gp130. IL-6 binds to the specific IL-6R and subsequently
induces homodimerization of gp130. In contrast, LIF, OSM,
CNTF, and IL-11 induce heterodimerization of gp130 with LIF
receptor, OSM receptor, or an as yet unidentified receptor
subunit (19, 20). Homo- or heterodimerization of gp130 leads
to activation of the JakySTAT signaling pathway (21–24).
In addition to the membrane-bound IL-6R, a naturally
occurring, soluble IL-6R (sIL-6R) can be generated by limited
proteolysis of the membrane protein (25–27) or by differential
splicing of the IL-6R pre-mRNA (28). The sIL-6R protein
together with IL-6 can activate target cells that express gp130
on their cell surface but lack membrane-bound IL-6R (29, 30).
This process has been called trans-signaling (29). In the
absence of the sIL-6R such cells are not able to respond to
IL-6. The potential biological importance of the sIL-6R is
underlined by its presence in serum and a number of inflam-
matory fluids (29).
We have examined the responses of cultured sympathetic
neurons to IL-6 and sIL-6R with regard to neuronal survival,
differentiation, and neurotransmitter and neuropeptide ex-
pression. Although the majority of sympathetic neurons ex-
press norepinephrine as their neurotransmitter, a small per-
centage of neurons, particularly those that innervate the sweat
glands, change transmitter and neuropeptide phenotype dur-
ing normal development to produce acetylcholine and vaso-
active intestinal peptide (VIP) (31, 32). Neuropoietic cyto-
kines, including CNTF, LIF, OSM, IL-11, and CT-1, induce the
same phenotypic changes of the neurotransmitter and neu-
ropeptide expression pattern in sympathetic neurons in vitro as
sweat glands do in vivo (31–33). In contrast, only minor effects
have been reported for IL-6 on these neurons (33, 34). During
development, sympathetic neurons acquire the ability to be
supported in vitro by LIF and CNTF by postnatal day 6 (35).
In contrast, maximal doses of IL-6 have no effect on the
survival of such neurons (34). We have investigated whether
sIL-6R can modulate the responsiveness of sympathetic neu-
rons to IL-6. For this purpose we used a highly active fusion
protein of sIL-6R and IL-6, covalently linked by a flexible
peptide chain, which is designated H-IL-6.
We show that primary cultures of neonatal rat sympathetic
neurons survive in nerve growth factor (NGF)-free culture
conditions after gp130 stimulation with sIL-6R. Furthermore,
these neurons synthesize and secrete IL-6, which can be
utilized only in the presence of exogenously supplied sIL-6R,
pointing to a new mechanism of neuronal stimulation that
depends on exogenously supplied sIL-6R.
MATERIALS AND METHODS
Chemicals. Recombinant human IL-6 was prepared as
described (36). Soluble human IL-6R and H-IL-6 were ex-
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pressed in the methylotrophic yeast Pichia pastoris and purified
as described (37, 38). NGF was isolated (39) with modifications
as described (40). The NGF antibody (Ab) was obtained as
described (40). The neutralizing IL-6 monoclonal antibody
(mAb) was a gift of J. Brakenhoff (41).
IL-6 Bioassay. The hybridoma growth factor activity of IL-6
was measured in the mouse B9 assay as described (42). Briefly,
B9 cells were washed three times in IL-6-free medium and
plated at a concentration of 5,000 cells per well in 50 ml, and
50 ml of cytokines was added. After 68 hr at 37°C, the number
of viable cells was measured by adding the tetrazolium salt
thiazolyl blue (MTT) and incubating for a further 4 hr at 37°C.
B9 cells were lysed by SDS and optical density was measured
at 570 nm. The amount of IL-6 present in the sample was
calculated by using an IL-6 standard curve generated by the
same procedure. Human IL-6 produces half-maximal prolif-
eration of B9 cells in this assay at 1 pgyml.
PC12 and NIH 3T3 Cells. Rat pheochromocytoma PC12
cells and mouse fibroblast NIH 3T3 cells were maintained as
monolayer cultures in Dulbecco’s modified Eagle’s medium
(DMEM; GIBCO) containing 10% heat-inactivated fetal calf
serum (Seromed) and 1% penicillin–streptomycin (GIBCO)
solution in a 5% CO2y95% air humidified atmosphere. The
medium was changed every 3 days and cells were subcultured
once a week. NIH 3T3 cells were stably transfected with the
expression vector pBMGNeo, carrying cDNA encoding the
extracellular domain of the rat gp80. Transcription of the
transfected gene under the control of the mouse metal-
lothionein promoter was induced by the addition of 10 mM
CdCl2 in serum-free medium for 18 hr. Supernatants of
transfected cells were collected and purified by Mono Q
Sepharose.
Primary Culture of Rat Sympathetic Neurons. Superior
cervical ganglia (SCG) were dissected from neonatal Sprague–
Dawley rats and decapsulated with forceps. Ganglia were
dissociated first with 0.3% trypsiny0.3% collagenasey0.03%
DNase I in L-15 medium (GIBCO) for 45 min at 37°C and then
with 0.3% trypsin for 15 min at 37°C. Cells were dispersed by
gently triturating through a fine-bore glass pipette and plated
in collagen-coated 96-well plates in L-15 mediumy2.5% adult
rat serum (GIBCO) with supplements as described previously
(43). To eliminate nonneuronal cells, cultures were treated
with 10 mM cytosine arabinonucleoside (Sigma) on days 2 and
6. After 7 days in culture approximately 95% of the cells were
neurons, according to morphological criteria. For reverse
transcriptase (RT)-PCR, dissociated sympathetic neurons
were seeded in 96-well plates at a density of 1 ganglion per well
and kept at 37°C and 5% CO2 in a humidified atmosphere (33,
44).
In Situ Hybridization. A rat IL-6 cDNA clone (ATCC 37681,
size 0.9 kb) was used for in vitro transcription and generation
of a cRNA probe. Digoxigenin (DIG)-labeled single-stranded
RNA probes, in sense or antisense orientation, were synthe-
sized from IL-6 cDNA template by the appropriate bacterial
RNA polymerase (T3 or T7 RNA polymerase) in the presence
of DIG-UTP (Boehringer Mannheim), as described by the
supplier. Probes were partly digested by alkaline hydrolysis to
improve cell penetration and were stored at 220°C. Hybrid-
ization and immunological detection were performed as de-
scribed (45). Sympathetic neuron cultures grown on collagen-
coated 4-chamber slides (Nunc) were fixed for 15 min in 4%
paraformaldehyde in PBS, permeabilized for 5 min by 0.2%
Triton X-100 in PBS, and acetylated for 10 min (0.1 M
triethanolaminezhydrochloridey0.25% acetic anhydride, pH
8.0). Prehybridization was carried out for 4–6 hr at room
temperature in hybridization buffer consisting of 50% form-
amide, 53 SSC, 53 Denhardt’s solution, 250 mgyml tRNA,
and 500 mgyml herring sperm DNA. For hybridization, 100–
200 ng of DIG-labeled cRNA probe per ml of hybridization
solution was denatured for 5 min at 80°C. Hybridization
proceeded for 16 hr at 37°C in a humid chamber. Slides were
then dipped in 53 SSC and washed under high-stringency
conditions for 60 min at 70°C in 0.23 SSC. After 5-min
equilibration in buffer 1 (0.1 M maleic acidy0.15 M NaCl, pH
7.5) and 60-min blocking with buffer 1 containing 2% fetal calf
serum and 0.3% Triton X-100, slides were incubated for 3–4
hr at room temperature with anti-DIG Ab conjugated to
alkaline phosphatase (diluted 1:2000) in a humid chamber.
Slides were rinsed twice with buffer 1 for 10 min and equili-
brated for 5 min in buffer 2 (0.1 M TriszHCly0.1 M NaCly5 mM
MgCl2, pH 9.5). To perform the color reaction, slides were
incubated with substrate solution [45 ml of nitroblue tetrazo-
lium (NBT; 100 mgyml), 35 ml of 5-bromo-4-chloro-3-indolyl
phosphate (50 mgyml), and 24 ml of levamisole (100 mgyml)
per 10 ml of buffer 2] overnight in a humid chamber protected
from light. This reaction was stopped by the addition of 10 mM
TriszHCl, pH 8.3y1 mM EDTA for 2 min. Slides were mounted
in aqua PolyMount (Polysciences), coverslipped, and sealed
with nail polish. Cells were examined with a phase-contrast
microscope (Zeiss).
RT-PCR. Neuronal culture, preparation of RNA and cDNA,
as well as the RT-PCR were done as previously described (33).
Dissociated sympathetic neurons were seeded in 96-well plates
in culture medium containing NGF, and aphidicolin (4 mgyml)
was added to eliminate nonneuronal cells. H-IL-6 and sIL-6R
were added from the second day of culture and duplicate wells
were prepared for each condition. Data were reproduced in
two separate neuronal platings. Total RNA and cDNA syn-
thesis as well as primer sequences and PCR conditions were as
described previously. Samples from the PCR were analyzed on
2% agarose gels, and the products were visualized with
ethidium bromide staining and UV illumination.
Soluble Rat IL-6R. A cDNA coding for a soluble rat IL-6R
was prepared by introducing a translational stop codon up-
stream of the transmembrane domain of the rat IL-6R. The
resulting sIL-6R cDNA was cloned in the eukaryotic expres-
sion vector pBMGNeo and used to stably transfect murine
NIH 3T3 cells. Supernatants of transfected cells were collected
and purified by Mono Q Sepharose. The resulting homoge-
neous protein was active in inducing the acute phase protein
haptoglobin in HepG2 human hepatoma cells upon addition of
rat or murine IL-6 (data not shown). In addition, a cDNA
coding for the extracellular portion of the rat IL-6R without
the signal peptide was cloned in the bacterial expression
plasmid rRSET5d (46) and expressed in Escherichia coli. The
band corresponding to the rat sIL-6R was cut out from a
polyacrylamide gel and used to immunize rabbits. This anti-
serum recognizes a protein of 55 kDa corresponding to the
soluble rat IL-6R secreted by the transfected NIH 3T3 cells.
RESULTS
We first asked whether IL-6 and sIL-6R can promote the
survival of dissociated sympathetic neurons in the absence of
NGF. For this purpose, we produced a fusion protein (H-IL-6)
consisting of human IL-6 and part of the human sIL-6R. This
protein is 100- to 1000-fold more effective than IL-6 and sIL6R
added as separate proteins (38). While no neurons survive in
the absence of NGF in control cultures, addition of H-IL-6
promotes long-term neuronal survival, at a level of 62% of that
seen with NGF (Fig. 1A). The effect of H-IL-6 is dose
dependent, with an optimal concentration of 10 ngyml (Fig.
1B). Interestingly, no inhibition of survival by doses up to 1000
ngyml was seen (data not shown).
The survival activities of NGF and H-IL-6 are blocked by
their respective neutralizing mAbs. The NGF response is
inhibited by the anti-NGF mAb 23c4 (40) (Fig. 1C) but not by
anti-IL-6 mAbs (41) (data not shown). Similarly, the H-IL-6
response is abrogated by anti-IL-6 but not by anti-NGF mAbs
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(Fig. 1C). These results suggest that the responses to NGF and
H-IL-6 do not depend on the release of the other protein.
We also determined whether H-IL-6 can regulate neuronal
gene expression as well as survival. A semiquantitative RT-
PCR assay using primers specific for cholecystokinin (CCK),
choline acetyltransferase (ChAT), enkephalin (ENK), galanin
(GLN), neuropeptide Y (NPY), somatostatin (SOM), sub-
stance P (SP), tyrosine hydroxylase (TH), vasoactive intestinal
polypeptide (VIP), and b-actin was used for this purpose (13,
33). The expression of b-actin is used to monitor the amount
of RNA in each sample. Addition of H-IL-6 induces an
expression pattern of mRNAs for neuropeptide and transmit-
ter biosynthetic enzymes very similar to that previously dem-
onstrated for LIF, CNTF, OSM, and CT-1 (47, 48) (Fig. 2).
Induction of mRNAs for ChAT, ENK, VIP, GLN, and SP are
clear at 1 ngyml H-IL-6. At 10 ngyml, H-IL-6 begins to induce
mRNAs for CCK and SOM. As with LIF and CNTF, H-IL-6
does not induce, but rather suppresses expression of NPY and
TH. The effect of H-IL-6 on VIP expression is complex; VIP
mRNA is induced by low concentrations of H-IL-6 but is
inhibited by high concentrations of H-IL-6 (Fig. 2). This
pattern was also observed for LIF (48). Two RNA species are
induced for SP, as was observed for LIF and CT-1 previously
(48). The apparent induction of GLN by sIL-6R shown in Fig.
2 was not observed in other experiments.
Because rat pheochromocytoma (PC12) cells synthesize and
secrete biologically active IL-6 (P.M., unpublished observa-
tion), we tested primary sympathetic neurons for this capacity.
Using both a species-specific ELISA and a biological assay
(42), we found that the medium from NGF- and H-IL-6-
supported neuronal cultures contained 200–600 pgyml IL-6
after 5 days (ELISA data in pgyml IL-6, n 5 3: 72 6 9
background; 216 6 18 neurons plus NGF; 533 6 123 neurons
plus H-IL-6) (B9 assay data in pgyml IL-6, n 5 3: 70 6 8
background; 571 6 101 neurons plus NGF). The medium from
neurons grown in H-IL-6 cannot be tested in the B9 assay
because human IL-6 stimulates B9 cell proliferation, whereas
the ELISA is species-specific for rat IL-6.
Despite the fact that very significant levels of IL-6 are found
in the culture medium, the neurons do not survive in the
absence of NGF. This result, coupled with our finding that
addition of the IL-6 fusion protein containing the IL-6R does
promote survival, suggests that the neurons are not expressing
FIG. 1. The IL-6–sIL-6R fusion protein H-IL-6 induces survival of
sympathetic neurons. (A) The time course of sympathetic neuron
survival after treatment with 100 ngyml NGF (), 10 ngyml H-IL-6
(F), 10 ngyml IL-6 (Q), or medium alone (h) is shown. Neuronal
survival was determined after 1, 3, and 6 days of culture by the MTT
assay. (B) Dose–response of sympathetic neurons treated with H-IL-6
for 5 days. Data are derived from three independent experiments (n 5
3). (C) Independence of the responses to NGF and IL-6ysIL-6R.
Dissociated sympathetic neurons were plated into medium containing
growth factors andyor neutralizing Abs as indicated for 6 days (100
ngyml NGF, 200 mgyml anti-NGF Ab 23c4, 10 ngyml H-IL-6, 10
mgyml anti-IL-6 Ab 16). Cultures were analyzed by the MTT assay. In
B and C, the OD obtained in the MTT assay for NGF-treated cells was
set at 100% and the OD measured for neurons treated with H-IL-6 was
expressed as percentage of this value. The data are derived from two
independent experiments (n 5 3).
FIG. 2. The IL-6–sIL-6R fusion protein H-IL-6 induces the cho-
linergic phenotype in sympathetic neurons. Various concentrations of
recombinant H-IL-6 or sIL-6R were added to neuronal cultures, and
the effects on neuronal gene expression were analyzed by RT-PCR.
The expression of b-actin is used to monitor the amount of RNA in
each sample. H-IL-6 induces mRNAs for substance P (SP), cholecys-
tokinin (CCK), choline acetyltransferase (ChAT), enkephalin (ENK),
galanin (GLN), and somatostatin (SOM), whereas sIL-6R alone has
no effect on these neuronal genes (the effect of the latter on GLN
expression was not reproducible). Neuropeptide Y (NPY) and tyrosine
hydroxylase (TH) expression were inhibited by H-IL-6, whereas
vasoactive intestinal polypeptide (VIP) expression was induced by low
concentrations of H-IL-6 and inhibited by high concentrations.
Neurobiology: Ma¨rz et al. Proc. Natl. Acad. Sci. USA 95 (1998) 3253
sufficient IL-6Rs for IL-6 autocrineyparacrine-driven survival.
To test this hypothesis further, we purified rat sIL-6R from
stably transfected NIH 3T3 cells. The dominant protein in the
supernatant (Fig. 3A, lane 1) was purified by ion-exchange
chromatography (Fig. 3A, lane 2). Its identity as sIL-6R was
verified by immunoblotting (Fig. 3B). Using the recombinant
sIL-6R, we increased the number of IL-6Rs on the neurons by
addition of the purified protein. As shown in Fig. 3C, 10 ngyml
sIL-6R promotes survival of the neurons, even in the absence
of exogenous IL-6. In fact, the effect of purified recombinant
rat sIL-6R is similar to that of the fusion protein H-IL-6 (Fig.
3C).
The finding that medium from sympathetic neuronal cul-
tures contains IL-6 is subject to the caveat that small numbers
of nonneuronal cells present may be responsible for the
cytokine production. To examine this issue, we used in situ
hybridization to localize the expression of IL-6 mRNA in the
cultures. Although no signal was detected by using an IL-6
sense probe, neurons identified as very large spherical cells
with long processes are clearly stained with an IL-6 antisense
probe (Fig. 4). IL-6 mRNA was also detected in neurons by in
situ hybridization on sections of adult rat SCG (49).
DISCUSSION
The major findings of this study are as follows: (i) cultured rat
sympathetic neurons express IL-6 mRNA and secrete biolog-
ically active IL-6; (ii) although these neurons do not express
IL-6Rs in sufficient quantity to allow the endogenous IL-6 to
drive autocrineyparacrine-mediated survival, addition of
sIL-6R does support survival using autocrineyparacrine IL-6;
and (iii) exogenous IL-6 regulates the same set of neuronal
genes controlled by the other members of the neuropoietic
cytokine family.
Much remains to be learned regarding IL-6 expression and
function in the nervous system (50, 51). Astrocytes and mi-
croglia can be stimulated in culture to produce IL-6 (52, 53),
raising the possibility that this cytokine may function in the
response to injury andyor infection. A variety of neurons have
been shown to respond to IL-6 addition in culture (5) and in
vivo (54). Where is IL-6 made in the normal, undisturbed
brain? Although IL-6 mRNA has been localized to certain
neurons in the brain and peripheral nervous system in vivo (49,
55, 56), there was no evidence that neurons can produce IL-6
protein. We demonstrate that neuron-alone cultures secrete
biologically active IL-6, and the neuronal localization of this
cytokine is supported by our finding that the neurons express
IL-6 mRNA.
These neurons also possess the downstream signaling path-
ways for IL-6 responsivity, as indicated by the effect of the IL-6
cytokine-receptor fusion protein (H-IL-6) on neuronal sur-
vival and neuropeptide induction. Moreover, when neuronal
IL-6 receptor levels are increased by the addition of sIL-6R,
these cells can also utilize their endogenous IL-6 for enhanced
survival in the absence of NGF (Fig. 3). Because sympathetic
neurons also express IL-6 mRNA in vivo, these findings raise
the possibility that IL-6 could be acting as an autocriney
paracrine factor for survival or changes in gene expression in
vivo as well. Studies on IL-6 knockout mice have not yet
reported on possible changes in sympathetic neuron survival or
function (57, 58).
Are receptor levels high enough to respond to IL-6 at
concentrations likely to occur in vivo? For instance, IL-6 is
found in peripheral tissues (1, 59) and is induced after injury
FIG. 3. Sympathetic neuron survival is stimulated by sIL-6R and
endogenous IL-6. (A) Silver-stained protein gel after SDSyPAGE of
supernatants of transfected cells (lane 1) and purified sIL-6R (lane 2).
(B) Western blot analysis of the gel shown in A, using a rabbit
antiserum raised against recombinant rat sIL-6R. (C) Neurons were
plated in medium (control), 100 ngyml NGF, 10 ngyml H-IL-6, 100
ngyml human IL-6 1 1 mgyml human sIL-6R, or 10 ngyml rat sIL-6R.
Six days after treatment, neuronal survival was determined by the
MTT assay.
FIG. 4. Expression of IL-6 mRNA by sympathetic neurons. Neu-
ronal localization of IL-6 mRNA in primary sympathetic neuron
cultures, using in situ hybridization and DIG-labeled cRNA probes for
IL-6 antisense (A) and IL-6 sense (B), is shown. Only the very large,
spherical cells with long processes were stained above background.
(3200.)
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to peripheral nerve (60–63). It would be of interest to know if
IL-6R is also induced in neurons under such circumstances. It
has recently been shown that the soluble form of the IL-6R is
generated by limited proteolysis and that the protease involved
is a membrane-associated metalloprotease (25–27), which is
regulated by protein kinase C (25, 64). Thus, stimuli that lead
to activation of protein kinase C could cause release of sIL-6R.
It remains to be determined which cells release sIL-6R or
whether levels of circulating sIL-6R (70 ngyml; ref. 65) are
sufficient to cause effects in neurons in vivo.
The observation that IL-6 can act as a cholinergic neuronal
differentiation factor (Fig. 2; ref. 66) raises the possibility that
this cytokine could be involved in the phenotypic switch driven
by sweat glands during normal sympathetic neuron develop-
ment (32). Analysis of IL-6 knockout mice could be informa-
tive in this regard.
The lack of an autocrineyparacrine effect of endogenous
IL-6 in sympathetic neurons is reminiscent of an earlier study
in which we stably transfected human hepatoma cells (HepG2)
with human IL-6 cDNA (67). Transfected cells that secrete
biologically active human IL-6 are not stimulated to produce
IL-6-responsive acute-phase proteins. When recombinant hu-
man sIL-6R is added to these cells, however, acute-phase
protein synthesis is induced. We speculated that binding of
IL-6 to IL-6R in the endoplasmic reticulum leads to the
down-regulation of endogenous IL-6R, and sIL-6R compen-
sates for the loss of endogenous IL-6R. Similarly, we recently
found that human lung fibroblasts synthesize and secrete IL-6
that does not lead to autostimulation of the cells, although the
cells can be stimulated by recombinant human sIL-6R (68). It
is also worth noting that another member of this cytokine
family, LIF, is produced by cultured sympathetic neurons, acts
in an autocrineyparacrine manner in this system, and is
expressed by these neurons in vivo (69).
The present results with the IL-6R fusion protein have
potential therapeutic implications. This fusion protein con-
taining human IL-6 and human sIL-6R connected by a flexible
protein linker has 100- to 1000-fold higher specific activity than
the components IL-6 and sIL-6R added separately (38). More-
over, the rat sIL-6RyIL-6 complex is considerably more active
in promoting sympathetic neuronal survival than LIF or CNTF
(35). It will therefore be of interest to test such constructs in
neurodegenerative disease and injury models.
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